We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.175 | 0.15 | 0.20 | 377,843 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -859k | -0.0010 | -1.70 | 1.43M |
From Jul 2021 to Jul 2024
TIDMNFX
RNS Number : 2273A
Nuformix PLC
01 February 2022
1 February 2022
Nuformix plc
("Nuformix" or the "Company")
Adviser Appointments
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Stanford Capital Partners Limited as Financial Adviser and Broker to the Company, with immediate effect.
Additionally, IFC Advisory Limited have been appointed as the Company's new financial public relations and investor relations adviser with immediate effect.
Enquiries:
Nuformix plc Dr Alastair Riddell, Executive Chairman Via IFC Advisory Stanford Capital Partners Limited Tom Price / Patrick Claridge (Corporate Finance) +44 (0) 20 3650 3650 John Howes (Corporate Broking) +44 (0) 20 3650 3652 IFC Advisory Limited Tim Metcalfe Zach Cohen +44 (0) 20 3934 6630
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPBKDBBCBKDQDN
(END) Dow Jones Newswires
February 01, 2022 01:59 ET (06:59 GMT)
1 Year Nuformix Chart |
1 Month Nuformix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
